The effect of aspirin and low-molecularweight heparin on venous thromboembolism after knee replacement
|
|
- Oswin Shepherd
- 5 years ago
- Views:
Transcription
1 S. S. Jameson, P. N. Baker, S. C. Charman, D. J. Deehan, M. R. Reed, P. J. Gregg, J. H. Van der Meulen From London School of Hygiene and Tropical Medicine, London, United Kingdom S. S. Jameson, MRCS, Research Fellow P. N. Baker, MSc, FRCS(Tr&Orth), Research Fellow The National Joint Registry for England and Wales, Tavistock Place, London WC1H 9SH, UK. S. C. Charman, MSc, Lecturer in Medical Statistics J. H. Van der Meulen, PhD, FFPH, Professor of Clinical Epidemiology The London School of Hygiene and Tropical Medicine, Tavistock Place, London WC1H 9SH, UK. D. J. Deehan, MD, MSc, FRCS(Tr&Orth), Consultant Newcastle Hospitals NHS Foundation Trust, Freeman Road, High Heaton, Newcastle upon Tyne NE7 7DN, UK. M. R. Reed, MD, FRCS(Tr&Orth), Consultant Northumbria Healthcare NHS Foundation Trust, Woodhorn Lane, Ashington, Northumberland NE63 9JJ, UK. P. J. Gregg, FRCS(Ed), FRCSEd(Orth), Consultant South Tees Hospitals NHS Foundation Trust, The James Cook Hospital, Marton Road, Middlesbrough TS4 3BW, UK. Correspondence should be sent to Mr S. S. Jameson; British Editorial Society of Bone and Joint Surgery doi: / x.94b $2.00 J Bone Joint Surg Br 2012;94-B: Received 13 January 2012; Accepted after revision 23 February 2012 KNEE The effect of aspirin and low-molecularweight heparin on venous thromboembolism after knee replacement A NON-RANDOMISED COMPARISON USING NATIONAL JOINT REGISTRY DATA We compared thromboembolic events, major haemorrhage and death after knee replacement in patients receiving either aspirin or low-molecular-weight heparin (LMWH). Data from the National Joint Registry for England and Wales were linked to an administrative database of hospital admissions in the English National Health Service. A total of patients between April 2003 and September 2008 were included and followed for 90 days. Multivariable risk modelling was used to estimate odds ratios adjusted for baseline risk factors (AOR). An AOR < 1 indicates that risk rates are lower with LMWH than with aspirin. In all, patients (23.1%) were prescribed aspirin and patients (76.9%) were prescribed LMWH. We found no statistically significant differences between the aspirin and LMWH groups in the rate of pulmonary embolism (0.49% vs 0.45%, AOR 0.88 (95% confidence interval (CI) 0.74 to 1.05); p = 0.16), 90-day mortality (0.39% vs 0.45%, AOR 1.13 (95% CI 0.94 to 1.37); p = 0.19) or major haemorrhage (0.37% vs 0.39%, AOR 1.01 (95% CI 0.83 to 1.22); p = 0.94). There was a significantly greater likelihood of needing to return to theatre in the aspirin group (0.26% vs 0.19%, AOR 0.73 (95% CI 0.58 to 0.94); p = 0.01). Between patients receiving LMWH or aspirin there was only a small difference in the risk of pulmonary embolism, 90-day mortality and major haemorrhage. These results should be considered when the existing guidelines for thromboprophylaxis after knee replacement are reviewed. Venous thrombosis is considered to be common following knee replacement, with the incidence of asymptomatic deep-vein thrombosis (DVT) being estimated to be as high as 60%. 1 However, the reported incidences of symptomatic venous thromboembolism (VTE, 1.8% 2 ) and fatal pulmonary embolism (PE, 0.15% 3 ) within 90 days of surgery are much lower. In order to reduce the occurrence of VTE, the National Institute for Health and Clinical Excellence (NICE) recommend combined mechanical and pharmacological prophylaxis post-operatively for ten to 14 days for all patients undergoing knee replacement, unless there are contraindications. 1 Recommended agents include lowmolecular-weight heparins (LMWHs), direct factor Xa inhibitors, fondaparinux sodium and unfractionated heparin (UFH). NICE state that the protective effect of aspirin against VTE is insufficient, and therefore do not recommend aspirin and other antiplatelet medications for pharmacological prophylaxis. Although this has also been the stance of the American College of Chest Physicians (ACCP) 4 and the International Consensus Group, 5 the American Academy of s (AAOS) in their guidelines were unable to find conclusive evidence to recommend one chemical prophylaxis agent over any other. 6 Recommendations against the use of aspirin are based on extrapolations from mostly small, historical studies. 7-9 Peri-operative care has subsequently evolved, and this evidence may now be outdated. More recent publications with larger numbers have suggested that the risk of VTE following either aspirin or injectable prophylaxis against VTE (LMWH/fondaparinux) is equivalent, 10 and the routine use of potent anticoagulants (LMWH/direct factor Xa inhibitors) does not reduce the overall mortality or the proportion of deaths due to PE. 11 Aspirin is an attractive method of prophylaxis as it is inexpensive, orally administered, and does not require laboratory monitoring. Prior to the NICE guidance almost a quarter of all patients undergoing knee replacement were given aspirin for VTE prophylaxis. 12 We have previously compared the effects of aspirin and LMWH on VTE after hip replacement, 13 showing a small survival benefit for 914 THE JOURNAL OF BONE AND JOINT SURGERY
2 THE EFFECT OF ASPIRIN AND LOW-MOLECULAR-WEIGHT HEPARIN ON VENOUS THROMBOEMBOLISM AFTER KNEE REPLACEMENT 915 those receiving LMWH, but no differences were seen for the risk of VTE and bleeding events. We now examine the role of these two chemical agents following total knee replacement (TKR) in a similar national series of patients. Patients and Methods We used records from the National Joint Registry for England and Wales (NJR) linked at patient level to records from the Hospital Episode Statistics (HES) database. The NJR aims to collect data prospectively on all patients who undergo knee replacement in England and Wales. 14 The HES database includes all patients admitted to NHS hospitals in England, or to private hospitals funded by the NHS (no Registry data from Wales was included in this analysis). 15 HES records contain patient details and diagnostic information coded using the International Classification of Diseases, tenth revision (ICD-10), 16 and operative procedure codes using the United Kingdom Office for Population Censuses and Surveys classification, fourth revision (OPCS-4). 17 The HES database also includes date of death from the Office for National Statistics. This analysis was based on data described in the Seventh NJR Annual Report. 12 We identified patients for whom a primary knee replacement (total, patellofemoral and unicompartmental) was recorded in the NJR between 1 April 2003 and 30 September 2009, and who could be linked to HES. The linkage was carried out based on a hierarchy of deterministic criteria, including NHS number, year of birth and gender, as detailed in the Seventh NJR Annual Report. 12 Of these, were given either aspirin or LMWH as the sole chemical thromboprophylaxis, irrespective of whether mechanical prophylaxis had also been used. Patients receiving more than one type of pharmacological prophylaxis were excluded. All patients were followed for at least 90 days. Information regarding the method of thromboprophylaxis was extracted from NJR records with relevant details of the operation and patient characteristics that were considered risk factors for VTE or haemorrhage. We used the Royal College of Surgeons Charlson Score 18 to search the HES database for comorbid conditions. HES data were also used to identify thromboembolic events (PE, DVT) and death within 90 days of surgery, major haemorrhage (cerebrovascular accident or gastrointestinal haemorrhage) and return to theatre for wound complications within 30 days of surgery. Minor haemorrhage was not considered, as it is unlikely to be accurately coded in the HES database. Statistical analysis. Logistic regression was used to assess the effect of treatment on outcome, with adjustment for patient characteristics that are risk factors for VTE or haemorrhage. Results are presented as odd ratios (OR) with 95% confidence intervals (CI); an OR < 1 indicates that rates are lower with LMWH than with aspirin. The likelihood ratio test was used as a basis for p-values, and p < 0.05 was considered to indicate statistical significance. All risk models included the type of pharmacological prophylaxis, age (grouped into three equal-sized categories with cut-off values rounded to the nearest multiple of five), gender, American Society of Anesthesiologists (ASA) grade, 19 number of comorbid conditions according to the Charlson score, indication for surgery (osteoarthritis or other), whether regional anaesthesia (epidural or spinal procedures) was used, type of prosthesis type (cemented TKR, cementless TKR, hybrid TKR, and unicompartmental or patellofemoral knee replacements), use of mechanical thromboprophylaxis, and provider type (NHS hospital, NHS treatment centre, independent hospital, or independent treatment centre). Use of regional anaesthesia was the only variable with missing values. In order to address this we used multiple imputation by chained equations. 20 Five datasets were created containing imputed values for missing values. Rubin s rules 21 were used to combine the estimation results based on each of these datasets. Results Of the patients who were eligible for inclusion, aspirin was used as thromboprophylaxis in (23.1%) and LMWH in (76.9%). Patients in the aspirin group were more likely than those in the LMWH group to receive mechanical prophylaxis and undergo treatment in an NHS hospital, but were less likely to have regional anaesthesia (Table I). The two groups were otherwise very similar. Without adjustment for potential risk factors, there was a significantly greater risk of return to theatre within 30 days in the aspirin group (OR 0.71 (95% CI 0.56 to 0.91)), although the absolute rate was low (aspirin 0.26% vs LMWH 0.19%). We found no statistically significant differences in the rate of thromboembolic events, 90-day mortality or major haemorrhage between the two groups (Table II). The rate of PE was 0.49% with aspirin and 0.45% with LMWH (unadjusted OR 0.91). The 90-day mortality was 0.39% with aspirin and 0.45% with LMWH (unadjusted OR 1.16). The differences in the other outcomes were small, and all unadjusted ORs varied around 1. After risk adjustment, return to theatre within 30 days remained significantly higher in the aspirin group (adjusted OR 0.73; p = 0.01). The impact of the risk adjustment on the differences in the other outcomes was small, and the groups had similar outcomes in terms of PE, DVT, 90-day mortality and major haemorrhage (Table II). Discussion In this large national cohort of patients undergoing knee replacement no significant differences were observed in the rates of VTE, 90-day mortality and major (cerebrovascular and gastrointestinal) haemorrhage when aspirin was compared with LMWH for prophylaxis. Within the constraints of the study design, we found that a significantly greater number of patients in the aspirin group returned to theatre for the management of wound complications within 30 days of the operation. VOL. 94-B, No. 7, JULY 2012
3 916 S. S. JAMESON, P. N. BAKER, S. C. CHARMAN, D. J. DEEHAN, M. R. REED, P. J. GREGG, J. H. VAN DER MEULEN Table I. Characteristics of the patients and their treatment according to pharmacological prophylaxis with aspirin or low-molecular-weight heparin (LMWH) Aspirin (n = ) LMWH (n = ) Gender (n, %) Male (42.3) (42.5) Female (57.7) (57.5) Age group (n, %) < 65 years (30.6) (29.4) 65 to 74 years (37.8) (38.1) 75 years (31.6) (32.5) ASA * grade (n, %) (15.1) (13.2) (70.2) (70.3) (14.7) (16.5) Charlson score (n, %) (71.5) (71.8) (23.7) (23.2) (4.2) 5252 (4.4) (0.6) 783 (0.7) Indication (n, %) Osteoarthritis (96.5) (97.0) Other 1285 (3.5) 3672 (3.0) Type of replacement (n, %) Cemented TKR (81.5) (85.0) Cementless TKR 2859 (7.9) 8085 (6.7) Hybrid TKR 300 (0.8) 1427 (1.2) Unicondylar 3004 (8.3) 7471 (6.2) Patellofemoral 516 (1.4) 1112 (0.9) Regional anaesthesia (n, %) Yes (52.8) (61.6) No (43.3) (32.4) Missing data 1399 (3.9) 7274 (6.0) Mechanical prophylaxis (n, %) Yes (83.5) (79.5) No 5970 (16.5) (20.5) Provider type (n, %) NHS hospital (88.8) (79.8) NHS treatment centre 1282 (3.6) (8.3) Independent hospital 2675 (7.4) 7038 (5.8) Independent treatment centre 85 (0.2) 7256 (6.0) * ASA, American Society of Anesthesiologists spinal or epidural The multivariable model included all available risk factors that were thought to be associated with the outcome, including adjusting risk for the presence or absence of mechanical prophylaxis. However, a number of unmeasured variables, known to influence VTE risk, could confound this analysis: obesity, cancer, previous VTE, family history, admission to intensive care, smoking, dehydration, thrombophilia, contraceptive use, and post-operative immobility. 1 If these higher-risk patients were more likely to have LMWH our results might underestimate the effect of LMWH. Unmeasured risk factors for bleeding may also influence the choice of prophylaxis. In addition, the NJR collects thromboprophylaxis data immediately post-operatively on an intention to treat basis. The agent given is not recorded, nor the dose, the duration of treatment or compliance. Data were unavailable on patients use of gastro-protective drugs. Patients who had a NJR record of knee replacement but lacked a matching record in the HES were excluded, thereby reducing the population studied. Furthermore, there are limitations in the ICD-10 and OPCS-4 coding systems, 22 and coding errors may underestimate event rates (as missing an event is more likely than incorrectly identifying one). Coding inaccuracies are especially relevant for DVT and wound infection, both of which are difficult to diagnose within the current limitations of HES. 23 We therefore used return to theatre codes as a surrogate for wound complications, including infection. However, rates of minor wound problems that did not require operative intervention, such as prolonged oozing, could not be quantified using the data available. Results from administrative data analyses must therefore be interpreted carefully. Regardless of these coding limitations, mortality as an outcome is well defined and therefore robust. Although asymptomatic DVT may occur in most patients after knee replacement, it is estimated that only around 1 in 21 of these will result in symptomatic VTE. 2 THE JOURNAL OF BONE AND JOINT SURGERY
4 THE EFFECT OF ASPIRIN AND LOW-MOLECULAR-WEIGHT HEPARIN ON VENOUS THROMBOEMBOLISM AFTER KNEE REPLACEMENT 917 Table II. Effect of aspirin and low-molecular-weight heparin (LMWH) on outcomes, with adjustment based on the multivariable risk model. An odds ratio (OR) < 1 indicates that rates are lower with LMWH than with aspirin (CI, confidence interval) Treatment group (n, %) Outcome Aspirin (n = ) LMWH(n = ) Unadjusted OR (95% CI) Adjusted OR (95% CI) p-value Pulmonary embolus 178 (0.49) 539 (0.45) 0.91 (0.77 to 1.08) 0.88 (0.74 to 1.05) 0.16 Deep-vein thrombosis 239 (0.66) 762 (0.63) 0.96 (0.83 to 1.11) 0.93 (0.81 to 1.08) 0.37 Death 140 (0.39) 540 (0.45) 1.16 (0.96 to 1.39) 1.13 (0.94 to 1.37) 0.19 Cerebrovascular accident/ 134 (0.37) 465 (0.39) 1.04 (0.86 to 1.26) 1.01 (0.83 to 1.22) 0.94 gastrointestinal haemorrhage Return to theatre 94 (0.26) 224 (0.19) 0.71 (0.56 to 0.91) 0.73 (0.58 to 0.94) 0.01 Reported rates of symptomatic VTE within 90 days of knee replacement are < 2%. 2,3 We found lower risks of DVT and PE, which may be explained by improvements in peri-operative care during the last decade. However, under-reporting may have played a role, as many DVTs are diagnosed in the outpatient clinic or in the community. There is currently limited evidence on the effects of thromboprophylaxis on the rates of PE following knee replacement, 10 and there is no significant evidence relating to fatal PE and death. 1 Moreover, no chemical thromboprophylaxis agent has been shown to be superior to others in terms of either efficacy or safety. 11 Guidelines are therefore based on evidence extrapolated from complex network analyses that provide indirect comparisons of symptomatic DVT rates that are difficult to interpret, and rely on the assumption that a reduction in DVT reduces the risk of fatal PE. In an independent systematic review of the same trials used by the ACCP to formulate their guidelines, Brown, 24 in contrast to the ACCP, concluded that aspirin was superior to LMWH. He found that the use of potent anticoagulants significantly increased the risk of post-operative bleeding without reducing clinically relevant symptomatic VTE and fatal PE rates compared to aspirin. Many of the studies analysed are historical and pre-date modern peri-operative care pathways. Admission on the day of surgery, early mobilisation and reduction in length of stay are all likely to contribute to a reduction in the risk of VTE. 10 The outcomes in these older VTE studies may not be representative of the current situation. Owing to the decreased baseline risks, the balance between harm and benefit of prophylaxis regimens will have changed. In addition, PE is not the leading cause of death after joint replacement, as was previously thought. In Scottish patients who underwent knee replacement between 1992 and 2001, acute myocardial infarction accounted for 36% of deaths compared to 18% for PE, 3 and when cause of death following almost joint replacements was analysed, cardiopulmonary disease (excluding PE) accounted for 48%, compared with 25% for PE, irrespective of thromboprophylaxis agent used. 11 We have previously reported findings from a similar comparison study of aspirin and LMWH in hip replacement patients. 13 Although a very small survival benefit was seen in the LMWH group, no differences in VTE events and major haemorrhage were found. There are only a few direct comparisons of the effects of aspirin and LMWH. Westrich et al 9 reported a non-significant difference in DVT rates in their randomised comparison of aspirin (DVT rate 17.8%) and LMWH (14.1%) when used in conjunction with mechanical prophylaxis. More recently Bozic et al 10 retrospectively compared rates of VTE, bleeding, infection and mortality in patients undergoing knee replacement using one of three pharmacological agents (aspirin n = 4719; LMWH/fondaparinux n = ; warfarin n = ). Once adjusted for case mix there were no significant differences for any outcomes between the aspirin and LMWH/fondaparinux groups. In NICE s network analysis of the risk reduction (RR) for DVT, the indirect comparison showed that aspirin and LMWH were equivalent when used in conjunction with mechanical devices (aspirin RR = 0.15, LMWH RR = 0.14). Although aspirin had the lowest bleeding risk of all prophylactic agents (aspirin: RR = 0.44 (95% CI 0.17 to 1.04); LMWH: RR = 1.23 (95% CI 0.91 to 1.68); fondaparinux: RR = 2.21 (95% CI 1.27 to 3.94)), the difference between aspirin and LMWH was non-significant owing to the limited evidence on which the calculations were based. 1 In this large cohort study of over knee replacements, patients receiving aspirin or LMWH had similar risks of pulmonary embolus, 90-day mortality and major haemorrhage. Despite a shift away from the use of aspirin as thromboembolic prophylaxis over the last ten years, it remains a viable alternative to LMWH for the prevention of VTE and mortality after knee replacement. Despite the limitations, this study provides further evidence for those engaged in the review of thromboprophylaxis guidelines for patients undergoing knee replacement. Supplementary material Two tables detailing i) the International Statistical Classification of Diseases and Related Health Problems (10th revision) (ICD-10) and Office of Population, Censuses and Surveys Classification of Surgical Operations and Procedures (4th revision) (OPCS-4) codes and ii) the Charlson score are available with the electronic version of this article on our website VOL. 94-B, No. 7, JULY 2012
5 918 S. S. JAMESON, P. N. BAKER, S. C. CHARMAN, D. J. DEEHAN, M. R. REED, P. J. GREGG, J. H. VAN DER MEULEN The authors would like to thank the patients and staff of all the hospitals in England and Wales who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR steering committee and the staff at the NJR centre for facilitating this work. The National Joint Registry for England and Wales is funded through a levy raised on the sale of hip and knee replacement implants. The cost of the levy is set by the NJR Steering Committee. The NJR Steering Committee is responsible for data collection. This work was funded by a fellowship from the National Joint Registry. The authors have conformed to the NJR s standard protocol for data access and publication. The views expressed represent those of the authors and do not necessarily reflect those of the National Joint Register Steering committee or the Health Quality Improvement Partnership (HQIP) who do not vouch for how the information is presented. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. References 1. No authors listed. National Institute For Health and Clinical Excellence. Nice clinical guideline 92: venous thromboembolism: reducing the risk, (date last accessed 24 February 2012). 2. Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007;5: Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg [Br] 2005;87-B: Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl): Cardiovascular Disease Educational and Research Trust, Cyprus Cardiovascular Disease Educational and Research Trust, European Venous Forum, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006;25: Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of s: preventing venous thrombembolic disease in patients undergoing elective hip and knee arthroplasty, VTE_full_guideline.pdf (date last accessed 24 February 2012). 7. Haas SB, Insall JN, Scuderi GR, Windsor RE, Ghelman B. Pneumatic sequential-compression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. J Bone Joint Surg [Am] 1990;72-A: McKenna R, Galante J, Bachmann F, et al. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J 1980;280: Westrich GH, Bottner F, Windsor RE, et al. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J Arthroplasty 2006;21(Suppl): Bozic KJ, Vail TP, Pekow PS, et al. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty 2010;25: Poultsides LA, Gonzalez Della Valle A, Memtsoudis SG, et al. Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. J Bone Joint Surg [Br] 2012;94-B: Ellams D, Forsyth O, Mistry A, et al.national Joint Registry for England and Wales: 7th annual report NJR%207th%20Annual%20Report% pdf (date last accessed 24 February 2012). 13. Jameson SS, Charman SC, Gregg PJ, Reed MR, van der Meulen JH. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry. J Bone Joint Surg [Br] 2011;94-B: Ellams D, Forsyth O, Hindley P, et al. National Joint Registry for England and Wales: 8th annual report Documents/NJR%208th%20Annual%20Report% pdf (date last accessed 24 February 2012). 15. No authors listed. The NHS Information Centre. Hospital activity: Hospital Episode Statistics, hospital-activity-hospital-episode-statistics--hes (date last accessed 24 February 2012). 16. No authors listed. World Heath Organisation: International Classification of Diseases (10th revision), (date last accessed 24 February 2012). 17. No authors listed. NHS Connecting for Health: OPCS-4 Classification, (date last accessed 24 February 2012). 18. Armitage JN, van der Meulen JH. Royal College of Surgeons Co-morbidity Consensus Group. Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score. Br J Surg 2010;97: No authors listed. New classification of physical status. Anesthesiology 1963;24: Royston P, Carlin JB, White IR. Multiple imputation of missing values: new features for mim. Stata J 2009;9: Rubin DB. Inference and missing data. Biometrika 1976;63: Raftery J, Roderick P, Stevens A. Potential use of routine databases in health technology assessment. Health Technol Assess 2005;9: Jameson SS, Baker PN, Gregg PJ, Reed MR, Deehan DJ. The use of national databases for the analyses of knee arthroplasty. Knee 2011;18: Brown GA. Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooled analysis of randomized controlled trials. J Arthroplasty 2009;24(Suppl): THE JOURNAL OF BONE AND JOINT SURGERY
AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS
The West London Medical Journal 2010 Vol 2 No 4 pp 19-24 AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS Soneji ND Agni NR Acharya MN Anjari
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationTITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms
TITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms DATE: 23 August 2011 CONTEXT AND POLICY ISSUES: Thromboembolism occurs when a blood
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationProphylaxis for Venous Thromboembolism Following Total Knee Arthroplasty: A Survey of Korean Knee Surgeons
Original Article Knee Surg Relat Res 2016;28(3):207-212 http://dx.doi.org/10.5792/ksrr.2016.28.3.207 pissn 2234-0726 eissn 2234-2451 Knee Surgery & Related Research Prophylaxis for Venous Thromboembolism
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationPage: 1 of 13. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Last Review Status/Date: March 2014 Page: 1 of 13 Compression Devices for Venous Description Patients undergoing major orthopedic surgery are at increased risk for venous thromboembolism (VTE). Patients
More informationNICE Guidance: Venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital 1
The College of Emergency Medicine Patron: HRH The Princess Royal Churchill House Tel +44 (0)207 404 1999 35 Red Lion Square Fax +44 (0)207 067 1267 London WC1R 4SG www.collemergencymed.ac.uk CLINICAL EFFECTIVENESS
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More information*Corresponding Author:
Audit of venous thromboembolism prophylaxis administered to general surgical patients undergoing elective and emergency operations at National Hospital, Sri Lanka *Migara Seneviratne 1, Asanka Hemachandra
More informationPostsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Clinical Position Statement Postsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Effective: October 2017 Next Review: September 2018 CLINICAL POSITION STATEMENT Postsurgical
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationTRANSPARENCY COMMITTEE OPINION. 18 April 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 April 2007 ARIXTRA 2.5 mg/0.5 ml, solution for injection in prefilled syringe Pack of 2 (CIP: 359 225-4) Pack of
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH President and CEO Dale W. Bratzler, DO, MPH Oklahoma Foundation for Medical Quality QIOSC Medical Director
More informationThe Royal College of Emergency Medicine. VTE Risk in Lower Limb Immobilisation in Plaster Cast 2015/2016
The Royal College of Emergency Medicine Clinical Audits VTE Risk in Lower Limb Immobilisation in Plaster Cast Introduction 2015/2016 EXCELLENCE IN EMERGENCY MEDICINE A significant number of patients attend
More informationTechnology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245
Apixaban for the prevention ention of venous thromboembolism after total hip or knee replacement in adults Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245 NICE 2018.
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationGeneral. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations
General Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationVenous thromboembolism after total knee replacement or total hip replacement: what can be learnt from root-cause analysis?
TRAUMA AND ORTHOPAEDIC SURGERY Ann R Coll Surg Engl 2016; 98: 538 542 doi 10.1308/rcsann.2016.0202 Venous thromboembolism after total knee replacement or total hip replacement: what can be learnt from
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More information1. SCOPE of GUIDELINE:
Page 1 of 35 CLINICAL PRACTICE GUIDELINE: Venous Thromboembolism (VTE) Prevention Guideline: Thromboprophylaxis AUTHORIZATION: VP, Medicine Date Approved: May 17, 2012 Date Revised: Vancouver Coastal Health
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationVenous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials
Winner of the AAHKS Award Venous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials Greg A. Brown, MD, PhD The Journal of Arthroplasty Vol. 24
More informationProtocol. Postsurgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Postsurgical Outpatient Use of Limb Compression Devices for (10128) (Formerly Outpatient Use of Limb Pneumatic Compression Devices for ) Medical Benefit Effective Date: 07/01/14 Next Review Date: 03/15
More informationBath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN (In Press)
Bath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN 0140-6736 (In Press) Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/1087/1/lancet_clots_1_20090522_4.pdf
More informationVenous thromboembolism - reducing the risk
Venous thromboembolism - reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital NICE guideline Draft for consultation,
More informationVenous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital
Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital VTE is common and dangerous 5 VTE is Common VTE Incidence: 1.5 / 1000 per year
More informationSUBJECT: LIMB PNEUMATIC COMPRESSION EFFECTIVE DATE: 06/27/13 DEVICES FOR VENOUS REVISED DATE: 06/26/14 THROMBOEMBOLISM PROPHYLAXIS
MEDICAL POLICY SUBJECT: LIMB PNEUMATIC COMPRESSION PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationVenous thromboembolism: reducing the risk
Issue date: January 2010 Venous thromboembolism: reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital This guideline
More informationNational Institute for Health and Clinical Excellence Health Technology Appraisal
National Institute for Health and Clinical Excellence Health Technology Appraisal Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs Comment
More information1/27/2016. Disclosure. Goals. The Risk and Prevention of Venous Thromboembolism (VTE) in Patients With Foot and Ankle Pathology
The Risk and Prevention of Venous Thromboembolism (VTE) in Patients With Foot and Ankle Pathology STEVEN STEINLAUF, MD THE ORTHOPAEDIC FOOT AND ANKLE INSTITUTE OF SOUTH FLORIDA CLINICAL ASSISTANT PROFESSOR
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationWhat You Should Know
1 New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know The American Society
More informationPRIMARY TOTAL KNEE & HIP
Clinical Guideline Version 2.0 Title: PRIMARY TOTAL KNEE & HIP Venous ThromboEmbolic (VTE) Guideline Target Audience: thopedic Surgeons and their Advanced Practice Practitioner partners; Hospitalists,
More informationAdam Goldfarb, M.A., D.C., D.E.S.S. Introduction
Venous Thromboembolism Prophylaxis following Lower Extremity Orthopedic Surgery: A Review of the Biomedical Research Literature and Evidence-Based Policy in the United States. Adam Goldfarb, M.A., D.C.,
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationMeasurement and Improvement of Quality of Cardiovascular Care DR : DEHESTANI
Measurement and Improvement of Quality of Cardiovascular Care DR : DEHESTANI Hospitals For hospitals in the United States, measures of cardiovascular care mandated by the Joint Commission have recently
More informationPage: 1 of 14. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Subject: Post-Surgical Outpatient Use of Limb Page: 1 of 14 Last Review Status/Date: March 2015 Post-Surgical Outpatient Use of Limb Compression Devices for Venous Description Patients undergoing major
More informationVenous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital
Please Note: This policy is currently under review and is still fit for purpose. Venous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital This procedural document supersedes
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationPost-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationORIGINAL RESEARCH. BACKGROUND: The clinical venous thromboembolism (VTE) burden remains high in the United States, despite guidelines
ORIGINAL RESEARCH Inpatient Thromboprophylaxis Use in U.S. Hospitals: Adherence to the Seventh American College of Chest Physician s Recommendations for At-risk Medical and Surgical Patients Alpesh N.
More informationVTE Prevention After Hip or Knee Replacement
This Clinical Resource gives subscribers additional insight related to the Recommendations published in May 2018 ~ Resource #340506 VTE Prevention After Hip or Knee Replacement The American College of
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More informationReducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge
Reducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge What is a venous thromboembolism (VTE)? This is a medical term that describes a blood clot that develops in a deep vein
More informationWhat evidence exists that describes the efficacy of mechanical prophylaxis for venous thromboembolism (VTE) in adult surgical patients?
July 2015 Rapid Review Evidence Summary McGill University Health Centre: Division of Nursing Research and MUHC Libraries What evidence exists that describes the efficacy of mechanical prophylaxis for venous
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationARTEMIS. ARixtra (fondaparinux) for ThromboEmbolism prevention in. a Medical Indications Study. NV Organon Protocol 63129
ARTEMIS ARixtra (fondaparinux) for ThromboEmbolism prevention in NV Organon Protocol 63129 a Medical Indications Study Objective To demonstrate efficacy and to assess safety of oncedaily subcutaneous (SC)
More informationPrimary VTE Prophylaxis. Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand
Primary VTE Prophylaxis Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand A 70-yr-old female before THA BMI 31 kg/m 2 with varicose vein What do you recommend for VTE prevention?
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationCorporate Medical Policy
Corporate Medical Policy Postsurgical Home Use of Limb Compression Devices for Venous File Name: Origination: Last CAP Review: Next CAP Review: Last Review: postsurgical_home_use_of_limb_ compression_devices_for_vte_prophylaxis
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationFINDINGS FROM THE GLOBAL ORTHOPAEDIC REGISTRY
Arthroplasty Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events FINDINGS FROM THE GLOBAL ORTHOPAEDIC
More informationA RETROSPECTIVE COHORT STUDY OF MEDIUM-TERM DATA FROM A NATIONAL JOINT REGISTRY
S. S. Jameson, P. N. Baker, J. Mason, P. J. Gregg, N. Brewster, D. J. Deehan, M. R. Reed From the School of Medicine and Health, Durham University, Durham, United Kingdom S. S. Jameson, MRCS, Research
More informationMore than 1 million total hip arthroplasties
Post-Discharge Venous Thromboembolism and Bleeding in a Large Cohort of Patients Undergoing Total Hip or Total Knee Arthroplasty Michael H. Huo, MD, Donna L. Spencer, PhD, Bijan J. Borah, MA, MSc, PhD,
More informationRisk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge
ORIGINAL CLINICAL INVESTIGATION Open Access Risk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge Li Wang 1, Nishan
More informationThe compliance of thromboprophylaxis affects the risk of venous thromboembolism in patients undergoing hip fracture surgery
DOI 10.1186/s40064-016-2724-1 RESEARCH The compliance of thromboprophylaxis affects the risk of venous thromboembolism in patients undergoing hip fracture surgery Yuan Gao 1, Anhua Long 2,3, Zongyan Xie
More informationAspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
More informationAudit of perioperative management of patients with fracture neck of femur
Audit of perioperative management of patients with fracture neck of femur *M Dissanayake 1, N Wijesuriya 2 Registrar in Anaesthesia 1, Consultant Anaesthetist 2, North Colombo Teaching Hospital, Ragama,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Postsurgical Home Use of Limb Compression Devices Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Postsurgical Home Use of Limb Compression
More informationCADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm
CADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm P. Timothy Pollak, MD, PhD University of Calgary Rocky Mountain/ACP Internal Medicine Meeting,
More informationPrimary VTE Thromboprophylaxis
Primary VTE Thromboprophylaxis Controversies in Hematology 53 rd Annual Meeting of Thai Society of Hematology Bundarika Suwanawiboon, MD Division of Hematology Department of Medicine Faculty of Medicine
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationPostsurgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Postsurgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Policy Number: 1.01.28 Last Review: 4/2018 Origination: 4/2013 Next Review: 4/2019 Policy Blue Cross and Blue
More informationNICE guideline Published: 21 March 2018 nice.org.uk/guidance/ng89
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism NICE guideline Published: 21 March 2018 nice.org.uk/guidance/ng89 NICE 2018. All rights
More informationIncidence of Venous Thromboembolism After Arthroscopic Anterior Cruciate Ligament Reconstruction
Incidence of Venous Thromboembolism After Arthroscopic Anterior Cruciate Ligament Reconstruction Masaki Nagashima 1,2 Toshiro Otani 3 Hiroyuki Seki 1,2 Kenichiro Takeshima 2 Nobuto Origuchi 4 Ken Ishii
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationDeep Vein Thrombosis
Deep Vein Thrombosis from NHS (UK) guidelines Introduction Deep vein thrombosis (DVT) is a blood clot in one of the deep veins in the body. Blood clots that develop in a vein are also known as venous thrombosis.
More informationNurse Initiated Sequential Compression Device Application Program for Total Knee Replacement Patient
Nurse Initiated Sequential Compression Device Application Program for Total Knee Replacement Patient Cheung Shuk Shan, Susana (APN,O&T, PYNEH) 15 May, 2013 Total Knee Replacement (TKR) TKR is a common
More informationThromboprophylaxis in Adult General Medical Patients - Guidelines for Management
Thromboprophylaxis in Adult General Medical Patients - Guidelines for Management Adapted from the Worcestershire Acute Hospitals NHS Trust Guideline WAHT-MED-010 Version: Final Ratified by: Provider Quality
More informationNational Bowel Cancer Audit Supplementary Report 2011
National Bowel Cancer Audit Supplementary Report 2011 This Supplementary Report contains data from the 2009/2010 reporting period which covers patients in England with a diagnosis date from 1 August 2009
More informationDENOMINATOR: All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES:
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationHospital Acquired VTE: update on national guidance
Hospital Acquired VTE: update on national guidance Rebecca Chanda Consultant Pharmacist - Thrombosis and Haemostasis Guy s and St Thomas Hospitals NHS Foundation Trust Chair of the UK Clinical Pharmacy
More informationMarch 31, Dear colleagues,
6300 North River Road Rosemont, IL 60018 p: 847-292-0530 f: 847-292-0531 www.ajrr.net March 31, 2014 Dear colleagues, The American Joint Replacement Registry (AJRR) has submitted materials to be considered
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationPrevalence of Symptomatic Venous Thrombo-Embolism in Patients with Total Contact Cast for Diabetic foot Complications A Retrospective Case Series.
Prevalence of Symptomatic Venous Thrombo-Embolism in Patients with Total Contact Cast for Diabetic foot Complications A Retrospective Case Series. Dr R King, Miss GE Jackson, Mr SR Platt Wirral University
More informationIncidence of Symptomatic Pulmonary Embolism in Spinal Surgery
Incidence of Symptomatic Pulmonary Embolism in Spinal Surgery Chatupon Chotigavanichaya MD*, Monchai Ruangchainikom MD*, Choompon Piyavanno MD*, Ekkapoj Korwutthikulrangsri MD*, Sirichai Wilartratsami
More informationGETTING IT RIGHT FIRST TIME National Professional Pilot
Professional Pilot South Tees Hospitals NHS Foundation Trust Constituent Hospitals: Friarage Hospital and The James Cook University Hospital Final Draft Provider Profile Report and Dashboard June 2014
More informationSUBJECT: LIMB PNEUMATIC COMPRESSION EFFECTIVE DATE: 06/27/13 DEVICES FOR VENOUS REVISED DATE: 06/26/14, 09/15/15,09/21/17. THROMBOEMBOLISM PROPHYLAXIS
MEDICAL POLICY REVISED DATE: 06/26/14, 09/15/15,09/21/17. PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationCPT only copyright 2014 American Medical Association. All rights reserved. 12/23/2014 Page 66 of 593
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2015 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationPerioperative VTE Prophylaxis
Perioperative VTE Prophylaxis Gregory J. Misky, M.D. Assistant Professor of Medicine University Of Colorado Denver You recommend the following 72 y.o. man admitted for an elective R hip repair. Patient
More informationEffective Health Care Program
Comparative Effectiveness Review Number 49 Effective Health Care Program Venous Thromboembolism Prophylaxis in Orthopedic Surgery Executive Summary Background ajor orthopedic surgery describes three surgical
More informationPRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES
PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES Mario Mandalà, MD Unit of Clinical Research Department of Oncology and Haematology Papa Giovanni XXIII Hospital Cancer Center
More informationUpdate on the risk of DVT during air travel - does the economy class syndrome really exist?
Update on the risk of DVT during air travel - does the economy class syndrome really exist? Thomas HW Stadlbauer Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University
More informationIndividualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationDiagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism
More information